On February 22, 2021 Ashvattha Therapeutics, a biotech company reported on targeting diseased tissues to minimize off target toxicity and expand the therapeutic index for a wide range of drugs using novel hydroxyl dendrimer therapeutics (HDT) (Press release, Ashvattha Therapeutics, FEB 22, 2021, View Source [SID1234575394]). Preclinical results on an HDT designed to target and image brain tumors and brain metastases after systemic administration will be presented at the AACR (Free AACR Whitepaper) Virtual Special Conference on Radiation Science and Medicine, held March 2-3, 2021.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The first AACR (Free AACR Whitepaper) Virtual Special Conference on Radiation Science and Medicine, in association with the AACR (Free AACR Whitepaper) Radiation Science and Medicine Working Group, will be an interdisciplinary review of the current and future use of radiation in cancer care. The conference research topics span basic, translational, and clinical radiation advances to foster discussions among radiation scientists at all career stages.
Full details of the virtual presentation are as follows:
Abstract Title: Selective Targeting and Imaging of Orthotopic Glioblastoma after a Single Systemic Dose of a Novel Hydroxyl Dendrimer Radionuclide
Date: March 2, 2021 on-demand
Location: AACR (Free AACR Whitepaper) Virtual Special Conference on Radiation Science and Medicine: View Source
"We’re excited to present this data at the first AACR (Free AACR Whitepaper) Special Conference on Radiation Science and Medicine, which shows that our novel HD imaging agent D-B483 (HD6-DOTA-111In) selectively targets brain tumors and metastases after a bolus IV injection. Noninvasive imaging techniques are important in diagnosing and treating brain cancer. We have demonstrated that D-B483 persists in the tumor for more than seven days, yielding a high signal (>8 fold) relative to normal brain tissue. We look forward to submitting an IND later this year, to evaluate D-B483 in patients with brain tumors and metastases," said Jeffrey Cleland, Ph.D., Chairman, Chairman, CEO & President at Ashvattha Therapeutics, "We will then be able to treat these patients with HDTs designed to treat the brain cancer."